Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19142094 | 0.80 | — | — | |
| SCHEMBL13605783 | 0.79 | KDM4E (0.46) | KDM4EALDH1A1HPGDGAALMNA | |
| SCHEMBL21296274 | 0.79 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDUSP2MAPT | |
| SCHEMBL23780884 | 0.78 | ERCC5 (0.49) | KDM4EALDH1A1HPGDLMNAMAPT | |
| SCHEMBL22705525 | 0.78 | CA2 (0.31) | ALDH1A1CA2CA9 | |
| SCHEMBL30455952 | 0.78 | ERCC5 (0.49) | KDM4EALDH1A1HPGDLMNAMAPT | |
| SCHEMBL27351381 | 0.78 | MAPT (0.42) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL14718066 | 0.76 | MEN1 (0.43) | KDM4EALDH1A1HPGDUSP2LMNA | |
| SCHEMBL21303861 | 0.74 | TSHR (0.46) | KDM4EALDH1A1HPGDGAALMNA | |
| SCHEMBL29926304 | 0.74 | TSHR (0.46) | KDM4EALDH1A1HPGDGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TP53, MCL1, VHL | F2R 4268/4885KDM4E 2144/4885ALDH1A1 535/4885 |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | TP53, MCL1, VHL | F2R 4268/4885KDM4E 2144/4885ALDH1A1 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.